Upon screening identification of Stanozolol, GC/HRMS confirmation of the suspicious sample is done by reanalysis of the urine specimen, where a specific immunoaffinity purification procedure is used to selectively isolate the long term excreted metabolites of Stanozolol. By meeting the specific identification criteria for more than one metabolite of the same parent compound, additional evidence could be obtained in the decision making process in doping control.